Skip to content
10-Q

Quarterly Report

CNBX PHARMACEUTICALS INC. CNBX

0001683168-24-004831

← back to feed
Filed
Jul 15, 2024 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2025 · Jul 14, 2024 31.11M sh
Cash And Equivalents Q3 2025 · May 31, 2024 $73.41K
Cash And Equivalents Q3 2025 · Aug 31, 2023 $129.7K
Current Liabilities Q3 2025 · May 31, 2024 $2.53M
Current Liabilities Q3 2025 · Aug 31, 2023 $2.52M
Current Assets Q3 2025 · May 31, 2024 $80.03K
Current Assets Q3 2025 · Aug 31, 2023 $224.31K
Total Assets Q3 2025 · May 31, 2024 $80.03K
Total Assets Q3 2025 · Aug 31, 2023 $499.04K
Shares Diluted Q3 2025 · May 31, 2023 9.27M sh
Shares Diluted Q3 2025 · May 31, 2023 4.03M sh
Operating Cash Flow Q3 2025 · May 31, 2023 −$133.04K
Stockholders Equity Q3 2025 · May 31, 2023 −$1.91M
Stockholders Equity Q3 2025 · Feb 28, 2023 −$2.01M
Stockholders Equity Q3 2025 · Aug 31, 2022 −$1.63M
Eps Diluted Q3 2025 · May 31, 2023 −$0.02
Eps Diluted Q3 2025 · May 31, 2023 −$0.78
Eps Basic Q3 2025 · May 31, 2023 −$0.02
Eps Basic Q3 2025 · May 31, 2023 −$0.78
Sga Expense Q3 2025 · May 31, 2023 $220.13K
Sga Expense Q3 2025 · May 31, 2023 $741.72K
Rd Expense Q3 2025 · May 31, 2023 $263.12K
Rd Expense Q3 2025 · May 31, 2023 $338.33K
Net Income Q3 2025 · May 31, 2023 −$154.69K
Net Income Q3 2025 · May 31, 2023 −$3.14M
Operating Income Q3 2025 · May 31, 2023 −$173.08K
Operating Income Q3 2025 · May 31, 2023 −$769.88K
Revenue Q3 2025 · May 31, 2023 $310.17K
Revenue Q3 2025 · May 31, 2023 $310.17K